Search Results

There are 7858 results for: content related to: Hepatitis E masquerading as drug-induced liver injury

  1. You have full text access to this OnlineOpen article
    Antidepressant activity of fingolimod in mice

    Pharmacology Research & Perspectives

    Volume 3, Issue 3, June 2015, Luigi di Nuzzo, Rosamaria Orlando, Cristina Tognoli, Paola Di Pietro, Giuseppe Bertini, Jessica Miele, Domenico Bucci, Marta Motolese, Sergio Scaccianoce, Alessandra Caruso, Gianluca Mauro, Carmine De Lucia, Giuseppe Battaglia, Valeria Bruno, Paolo Francesco Fabene and Ferdinando Nicoletti

    Article first published online : 24 MAY 2015, DOI: 10.1002/prp2.135

  2. Fingolimod for relapsing-remitting multiple sclerosis

    Intervention Review

    The Cochrane Library

    Loredana La Mantia, Irene Tramacere, Belal Firwana, Ilaria Pacchetti, Roberto Palumbo and Graziella Filippini

    Published Online : 19 APR 2016, DOI: 10.1002/14651858.CD009371.pub2

  3. Population Pharmacokinetics of Fingolimod Phosphate in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 52, Issue 7, July 2012, Pages: 1054–1068, Dr Kai Wu, Dr Francois Mercier, Dr Olivier J. David, Dr Robert L. Schmouder and Dr Michael Looby

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270011409229

  4. Pharmacodynamic Effects of Steady-State Fingolimod on Antibody Response in Healthy Volunteers: A 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study

    The Journal of Clinical Pharmacology

    Volume 52, Issue 12, December 2012, Pages: 1879–1890, Mr Craig Boulton, Dr Karin Meiser, Dr Olivier J. David and Dr Robert Schmouder

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270011427908

  5. Japanese guidelines for fingolimod in multiple sclerosis: Putting into practice

    Clinical and Experimental Neuroimmunology

    Volume 5, Issue 1, February 2014, Pages: 34–48, Makoto Matsui, Yuko Shimizu, Hikaru Doi, Ryo Tomioka, Ichiro Nakashima, Masaaki Niino and Jun-ichi Kira

    Article first published online : 27 FEB 2014, DOI: 10.1111/cen3.12080

  6. What we know and do not know about fingolimod: Outline and interpretation of results from the Japanese fingolimod core and extension studies

    Clinical and Experimental Neuroimmunology

    Volume 5, Issue 1, February 2014, Pages: 10–18, Jun-ichi Kira

    Article first published online : 27 FEB 2014, DOI: 10.1111/cen3.12098

  7. You have full text access to this OnlineOpen article
    Fingolimod treatment promotes regulatory phenotype and function of B cells

    Annals of Clinical and Translational Neurology

    Volume 2, Issue 2, February 2015, Pages: 119–130, Berit Grützke, Stephanie Hucke, Catharina C. Gross, Martin V. B. Herold, Anita Posevitz-Fejfar, Brigitte T. Wildemann, Bernd C. Kieseier, Thomas Dehmel, Heinz Wiendl and Luisa Klotz

    Article first published online : 16 JAN 2015, DOI: 10.1002/acn3.155

  8. You have free access to this content
    Effect of fingolimod (FTY720) on cerebral blood flow, platelet function and macular thickness in healthy volunteers

    British Journal of Clinical Pharmacology

    Volume 78, Issue 6, December 2014, Pages: 1354–1365, Magdalena Ocwieja, Karin Meiser, Olivier J. David, Jessica Valencia, Frank Wagner, Stephan J. Schreiber, Uwe Pleyer, Sabine Ziemer and Robert Schmouder

    Article first published online : 20 NOV 2014, DOI: 10.1111/bcp.12454

  9. Ketoconazole Increases Fingolimod Blood Levels in a Drug Interaction via CYP4F2 Inhibition

    The Journal of Clinical Pharmacology

    Volume 49, Issue 2, February 2009, Pages: 212–218, Dr John M. Kovarik, Mr Kiran Dole, Dr Gilles-Jacques Riviere, Dr Francoise Pommier, Mr Steve Maton, Mr Yi Jin, Dr Kenneth C. Lasseter and Dr Robert L. Schmouder

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270008329553

  10. Fingolimod (FTY720) in Severe Hepatic Impairment: Pharmacokinetics and Relationship to Markers of Liver Function

    The Journal of Clinical Pharmacology

    Volume 46, Issue 2, February 2006, Pages: 149–156, Dr John M. Kovarik, Dr Robert L. Schmouder, Dr Stefan Hartmann, Dr Gilles-Jacques Riviere, Dr Franck Picard, Dr Brigitta Voss, Dr Markus Weiss, Dr Frank Wagner and Dr Hartmut H.-J. Schmidt

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270005283464

  11. You have free access to this content
    The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 66, Issue 2, August 2008, Pages: 199–206, John M. Kovarik, Alan Slade, Gilles-Jacques Riviere, Daniel Neddermann, Steve Maton, Thomas L. Hunt and Robert L. Schmouder

    Article first published online : 11 APR 2008, DOI: 10.1111/j.1365-2125.2008.03199.x

  12. A Mechanistic Study to Assess Whether Isoproterenol Can Reverse the Negative Chronotropic Effect of Fingolimod

    The Journal of Clinical Pharmacology

    Volume 48, Issue 3, March 2008, Pages: 303–310, Dr Joh M. Kovarik, Dr Gilles-Jacques Riviere, Dr Daniel Neddermann, Mr Steve Maton, Dr Thoma L. Hunt and Dr Rober L. Schmouder

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270007312903

  13. You have free access to this content
    Modulation of IL-33/ST2-TIR and TLR Signalling Pathway by Fingolimod and Analogues in Immune Cells

    Scandinavian Journal of Immunology

    Volume 80, Issue 6, December 2014, Pages: 398–407, K. Rüger, F. Ottenlinger, M. Schröder, A. Živković, H. Stark, J. M. Pfeilschifter and H. H. Radeke

    Article first published online : 26 NOV 2014, DOI: 10.1111/sji.12238

  14. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects

    Biopharmaceutics & Drug Disposition

    Volume 28, Issue 2, March 2007, Pages: 97–104, John M. Kovarik, Stefan Hartmann, Michael Bartlett, Gilles-Jacques Riviere, Daniel Neddermann, Yibin Wang, Andreas Port and Robert L. Schmouder

    Article first published online : 18 JAN 2007, DOI: 10.1002/bdd.535

  15. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

    Annals of Neurology

    Volume 69, Issue 5, May 2011, Pages: 759–777, Jeffrey A. Cohen and Jerold Chun

    Article first published online : 22 APR 2011, DOI: 10.1002/ana.22426

  16. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients

    Annals of Neurology

    Volume 69, Issue 2, February 2011, Pages: 408–413, Matthias Mehling, Patricia Hilbert, Stefanie Fritz, Bojana Durovic, Dominik Eichin, Olivier Gasser, Jens Kuhle, Thomas Klimkait, Raija L.P. Lindberg, Ludwig Kappos and Christoph Hess

    Article first published online : 8 MAR 2011, DOI: 10.1002/ana.22352

  17. Future directions in the study of fingolimod in multiple sclerosis

    Clinical and Experimental Neuroimmunology

    Volume 5, Issue 1, February 2014, Pages: 55–60, Akio Suzumura

    Article first published online : 27 FEB 2014, DOI: 10.1111/cen3.12090

  18. Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma

    Clinical Pharmacology in Drug Development

    Volume 2, Issue 1, January 2013, Pages: 2–10, Craig Boulton, Olivier J. David, Karin Meiser and Robert Schmouder

    Article first published online : 4 MAR 2013, DOI: 10.1002/cpdd.4

  19. Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm

    The Journal of Clinical Pharmacology

    Volume 55, Issue 9, September 2015, Pages: 1051–1060, Sonja Krösser, Peter Wolna, Tanya Z. Fischer, Ursula Boschert, Randall Stoltz, Meijian Zhou and Borje Darpo

    Article first published online : 25 MAY 2015, DOI: 10.1002/jcph.513

  20. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants

    Pediatric Transplantation

    Volume 15, Issue 4, June 2011, Pages: 406–413, R. Ettenger, R. Schmouder, J. M. Kovarik, M. C. Bastien and P. F. Hoyer

    Article first published online : 17 MAY 2011, DOI: 10.1111/j.1399-3046.2011.01498.x